Navigation Links
Humanized Antibody Therapy Found Highly Effective in Easing RA Symptoms

Medical University of Vienna researchers have shown that nearly half of patients with rheumatoid arthritis (RA), who receive tocilizumab in addition to ongoing methotrexate therapy , showed a 50 per cent improvement in the symptoms at 24 weeks.

Also one fifth of the patients achieved a 70 per cent improvement in symptoms in the same period during the study, which was presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona.

These data show the potential of tocilizumab as a novel and attractive approach to treating RA. The symptom improvements observed across both 4mg/kg and 8mg/kg doses show that tocilizumab offers significant promise to patients with moderate and severe RA, said lead researcher Dr. Josef Smolen.

The researchers say that significant improvement in symptoms was observed in all patients receiving tocilizumab and methotrexate, compared to placebo and methotrexate.

They observed that 79.5 per cent of patients receiving tocilizumab 8mg/kg, and 61.9 per cent receiving 4mg/kg tocilizumab had achieved a good/moderate EULAR response, in comparison with placebo subjects.

A reduction in Disease Activity Score was also observed from two weeks onwards in both tocilizumab groups, say the researchers.

The study involved 623 patients with sustained moderate to severe RA despite long standing treatment with methotrexate. The subjects were permitted concurrent treatment with methotrexate at their pre-study dose, though treatment with all other disease modifying anti-rheumatic drugs was discontinued at the beginning of the trial.

Tocilizumab is a novel humanised anti human interleukin 6 (IIL-6) receptor monoclonal antibody, a cytokine involved in the pathogenesis of RA.


'"/>




Page: 1

Related medicine news :

1. Human Antibody That Can Block SARS
2. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
3. Cuba Registers New Antibody
4. Single Sugar Enables Antibody to Treat Inflammation
5. Monoclonal Antibody based system for Anthrax detection
6. Monoclonal Antibody Reduces Exacerbations in Asthmatics
7. Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels
8. Antibody Therapy Prevents Type 1 Diabetes
9. New Antibody for EGFR Causes Lung Cancer Regression
10. J591- an Antibody Exclusively Targets Tumors
11. Antibody-based Therapies Effective at Controlling Malaria
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2017)... ... 2017 , ... Sterling Global Products is pleased to welcome ... hanging flushable wipes dispensers and/or 42 count refill packs manufactured by this Slidell, ... operates more than 350 stores throughout Texas and expanding into northern Mexico as ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... with the Home Care Association of America (HCAOA). This agreement allows HCAOA members ... services, as well as discounts on Accreditation University (AU) educational resources that help ...
(Date:4/28/2017)... ... ... affects much more than energy – it also has mental and physical benefits. According to ... time, which can increase the risk of having a car accident. , This week ... to help you sleep better and feel better:, , Turn off ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery ... the revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, ... patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional ...
(Date:4/28/2017)... ... 2017 , ... People are starting to accept that hearing aids can be ... the stigma it had when great-grandpa wore his hearing aids years ago,” said Dr. ... North American Speaker Series (NASS) segment. β€œHe probably wore an iPod-size hearing ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
Breaking Medicine Technology: